Innovent Biologics, Inc. IVBXF
10.07 USD -0.46 (-4.39%)
At closeNov 3, 2026, 4:00 PM EST
10.35 Day range 10.35
9.10 52-week range 15.01
- YTD
- +3.28%
- 1 year
- -5.45%
News
benzinga.com Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China Innovent Biologics, Inc. and Eli Lilly and Co. (NYSE:LLY) on Tuesday entered into a distribution and promotion agreement for Eli Lilly's breast cancer therapy Verzenios (abemaciclib) in mainland…
reuters.com China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said…
reuters.com Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a…
prnewswire.com Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026 SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and…
prnewswire.com Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma SAN FRANCISCO and SUZHOU, China, June 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and…
cnbc.com Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in…
reuters.com China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal Chinese biopharmaceutical firm Innovent Biologics and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12…
prnewswire.com 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable S SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and…
prnewswire.com 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and…
prnewswire.com Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent…
prnewswire.com Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and…
prnewswire.com Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and…
prnewswire.com Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer SAN FRANCISCO and SUZHOU, China, May 10, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and…
prnewswire.com Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting SAN FRANCISCO and SUZHOU, China, April 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and…
prnewswire.com Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases SAN FRANCISCO and SUZHOU, China, April 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and…
prnewswire.com Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to…
prnewswire.com Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and…
seekingalpha.com Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies U.S. considers global AI chip export restrictions, impacting Nvidia and AMD as shares fall on regulatory risk. A 30-day U.S. waiver allows India to purchase stranded Russian crude, aiming to…
defenseworld.net Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Up 88.4% in February Innovent Biologics, Inc. (OTCMKTS:IVBXF - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling…
wsj.com Innovent Biologics Strikes Partnership Deal With Eli Lilly Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.